Drug: NW-301D
Phase 1Small molecule
Drug: NW-301D is one of 89 small molecule programs targeting Adenocarcinoma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
90 competitors in Adenocarcinoma
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Gemzar
Johnson & JohnsonPhase 3
Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Taxotere
AAvyxa
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Beyfortus
BeiGenePhase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
PD-1 Inhibitor
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Drug: NW-301D. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- PPeking University